Relationship between low‐density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid‐lowering …
J Rey, F Poitiers, T Paehler, A Brunet… - Journal of the …, 2016 - Am Heart Assoc
Background Alirocumab undergoes target‐mediated clearance via binding of proprotein
convertase subtilisin/kexin type 9 (PCSK 9). Statins increase PCSK 9 levels; the effects of …
convertase subtilisin/kexin type 9 (PCSK 9). Statins increase PCSK 9 levels; the effects of …
Randomized, partial blind study of the pharmacodynamics, pharmacokinetics and safety of multiple subcutaneous doses of alirocumab, a fully human monoclonal …
J Rey, F Poitiers, T Paehler, A Brunet… - Journal of the American …, 2014 - jacc.org
Background Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibodies
such as alirocumab undergo target mediated clearance by binding PCSK9. Statins are …
such as alirocumab undergo target mediated clearance by binding PCSK9. Statins are …
[HTML][HTML] Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated …
DJ Kereiakes, JG Robinson, CP Cannon… - American heart …, 2015 - Elsevier
Background The ODYSSEY COMBO I study (http://clinicaltrials. gov/show/NCT01644175)
evaluated efficacy and safety of alirocumab as add-on therapy to stable maximally tolerated …
evaluated efficacy and safety of alirocumab as add-on therapy to stable maximally tolerated …
[HTML][HTML] Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
JG Robinson, M Farnier, M Krempf… - … England Journal of …, 2015 - Mass Medical Soc
Background Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–
kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol …
kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol …
[HTML][HTML] Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
JJP Kastelein, DJ Kereiakes, CP Cannon… - Coronary artery …, 2017 - journals.lww.com
Objectives The objective of this study is to report the dose response in ODYSSEY phase 3
clinical trials of proprotein convertase subtilisin kexin type 9 inhibition with alirocumab in …
clinical trials of proprotein convertase subtilisin kexin type 9 inhibition with alirocumab in …
A 24-week study of alirocumab as monotherapy versus ezetimibe: the first Phase 3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor
EM Roth, MR Taskinen, H Ginsberg, J Kastelein… - Journal of the American …, 2014 - jacc.org
Background Alirocumab is a fully human monoclonal antibody to proprotein convertase
subtilisin/kexin type 9 (PCSK9). The aim of this 24-week trial (NCT01644474; ODYSSEY …
subtilisin/kexin type 9 (PCSK9). The aim of this 24-week trial (NCT01644474; ODYSSEY …
[HTML][HTML] Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II)
The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to
substantially reduce low-density lipoprotein cholesterol (LDL-C). Demonstrating whether …
substantially reduce low-density lipoprotein cholesterol (LDL-C). Demonstrating whether …
Efficacy and safety of different dosing regimens of alirocumab (starting doses of 75 mg every two weeks and 150 mg every four weeks) versus placebo in patients with …
ESG Stroes, J Guyton, M Farnier, N Lepor… - Journal of the American …, 2015 - jacc.org
Background: Statins upregulate PCSK9 and increased PCSK9 accelerates target-mediated
clearance of PCSK9 monoclonal antibodies; this may limit sustained efficacy when …
clearance of PCSK9 monoclonal antibodies; this may limit sustained efficacy when …
[HTML][HTML] Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials
AL Catapano, LV Lee, MJ Louie, D Thompson… - Scientific reports, 2017 - nature.com
Low-density lipoprotein cholesterol (LDL-C) reductions with the PCSK9 monoclonal
antibody alirocumab may be affected by background statin dose due to increased PCSK9 …
antibody alirocumab may be affected by background statin dose due to increased PCSK9 …
[HTML][HTML] ODYSSEY EAST: alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin …
Y Han, J Chen, VK Chopra, S Zhang, G Su… - Journal of clinical …, 2020 - Elsevier
Background The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab
significantly reduces low-density lipoprotein cholesterol (LDL-C). Objective This study …
significantly reduces low-density lipoprotein cholesterol (LDL-C). Objective This study …